Myricx Bio is a biotechnology company based in London that specializes in the development of a novel class of antibody-drug conjugates (ADCs) utilizing inhibitors of N-myristoyltransferases (NMT). These inhibitors target a specific enzyme responsible for lipid modifications on proteins that are crucial for cancer cell survival. Myricx Bio's proprietary pipeline of ADCs aims to address significant unmet needs in oncology, demonstrating promising preclinical efficacy and safety across various solid tumor-associated antigens and cancer cell types. The company is focused on advancing its NMT inhibitor (NMTi) payload platform through clinical proof of concept.

Recently, Myricx Bio has relocated its headquarters to the London Innovation Centre, a state-of-the-art facility that provides flexible laboratory and office spaces tailored for life sciences organizations. This move follows a successful £90 million Series A financing round, which will support the company's growth and research capabilities. The London Innovation Centre is part of a broader life sciences ecosystem in Canary Wharf, fostering collaboration and innovation among various biotech companies. Myricx Bio's strategic positioning within this vibrant community is expected to enhance its development efforts and facilitate its transition to a clinical-stage company.

United Kingdom

Myricx Bio is a biotech company headquartered in London, focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs). They are focused on the discovery and development of a completely novel class of selective cytotoxic payloads for ADCs.

Myricx Bio

Company Details